John Neis is a Managing Director and heads the firm’s Healthcare practice. He teamed up with Roger Ganser in the formative stages of Venture Investors in 1985, and his decades of industry experience have enabled him to experience several industry cycles, and to serve on the Board of Directors of companies from formation through IPO or sale.
John currently serves on the Boards of Directors of Virent, Deltanoid Pharmaceuticals, Great Lakes Pharmaceuticals, and Cellectar Biosciences. He is a former member of the Boards of Directors of several firms including TomoTherapy (acquired by Accuray following an IPO), Third Wave Technologies (acquired by Hologic following an IPO), NimbleGen Systems (acquired by Roche) and Inviragen (acquired by Takeda).
John was appointed by the Governor to the Board of the Wisconsin Technology Council, which is the science and technology advisor to the Governor and Legislature. He also serves on the advisory boards for the Weinert Applied Ventures Program, the University of Wisconsin-Madison Business School and Tandem Press. He was a member of the patent advisory group of the National Venture Capital Association. His achievements were recognized when he was named to the 2008 and 2009 Midas Lists, Forbes annual listing of the top 100 tech dealmakers in the world.
John graduated Magna Cum Laude with a B.S. in Finance from the University of Utah, and received a M.S. in Marketing and Finance from the University of Wisconsin–Madison. He is a Chartered Financial Analyst.